Authors
Latest:
Dr. Burgess on PARP Resistance in Ovarian CancerBrian T. Burgess, DO, first-year fellow, University of Kentucky Markey Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.
Latest:
Future Perspectives on the Treatment Landscape for CLLA panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.
Latest:
Dr. Patterson on Off-Target Effects With TKIs in Pediatric CMLBriana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses the off-target effects with tyrosine kinase inhibitors (TKIs) in pediatric patients with chronic myeloid leukemia (CML).
Latest:
On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone TherapiesA new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.
Latest:
Dr. Koontz on Next Steps for Study of LHRH in Prostate CancerBridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.
Latest:
Bridgett Harr on Managing Long-term Side Effects in Head and Neck CancerBridgett Harr, CNP, radiation oncology, Cleveland Clinic, discusses survivorship and managing long-term side effects in head and neck cancer.
Latest:
Targeted Treatment Provides ORR and PFS Benefit in Pretreated Metastatic Solid TumorsTargeted treatment as determined by mutational status was associated with ORR and PFS benefits in pretreated patients with metastatic solid tumors.
Latest:
Persistence and the Quest for Innovation Guided a Radiotherapy PioneerHerman D. Suit, MD, MSc, PhD, a leader in the field of radiation oncology whose innovations lessened the need for radical surgery and improved outcomes for patients, was honored in the Radiation Oncology category with a 2017 Giants of Cancer Care® award.
Latest:
Dr. Brigid Killelea on Nipple-Sparing Mastectomy for Breast CancerBrigid Killelea, MD, MPH, FACS, associate professor of surgery (oncology), Yale Cancer Center, discusses the potential of nipple-sparing mastectomy for women who undergo surgery for breast cancer.
Latest:
NO-Naproxen May Protect Against Colorectal CancerA study presented at the AACR 101st Annual Meeting 2010 by researchers from the Fox Chase Cancer Center, Philadelphia, Pennsylvania, provides further evidence that non-steroidal anti-inflammatory drugs (NSAIDs) are promising chemopreventive agents with activity against colorectal cancer.
Latest:
Dr. Basu on Second-Line Therapy in HCCBristi Basu, MD, honorary consultant medical oncologist, University of Cambridge, discussed second-line therapy for patients with hepatocellular carcinoma.
Latest:
Biomarkers in Ovarian Cancer: Early Detection and ChemoresistanceWorldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.
Latest:
Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian CancerJoshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.
Latest:
DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLCExpression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.
Latest:
Dr. O'Neil on Standard of Care in Muscle-Invasive Bladder CancerBrock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the current standard of care in muscle-invasive bladder cancer.
Latest:
Brock Schroeder Discusses BCI Findings in ER+ Breast CancerBrock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.
Latest:
Dr. Bruce D. Cheson on Obinutuzumab/ Bendamustine Survival Benefit in iNHLBruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).
Latest:
Dr. Raphael on the Clinical Implications of the CLL14 TrialBruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Latest:
Dr. Levine on Programmed Anticancer Immunity With T-cell and NK-cell TherapiesBruce L. Levine, PhD, discusses engineered anticancer immunity with T-cell and natural killer–cell therapies.
Latest:
Dr. Roth on the Treatment of Cancers With BevacizumabBruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the treatment of several cancers with bevacizumab.
Latest:
Dr. Daniele on Impact of Regorafenib in HCCBruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).
Latest:
Dr. Sangro on Updated Findings From the CheckMate-459 Trial in Advanced HCCBruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.
Latest:
Dr. Mehlhaff on the Evolution of the Treatment Landscape in Prostate CancerBryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the ways in which the treatment landscape in prostate cancer has evolved in recent years.
